INVESTIGADORES
REFOJO Damian
artículos
Título:
Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk
Autor/es:
PAEZ-PEREDA M,; GIACOMINI D,; REFOJO D,; NAGASHIMA AC,; HOPFNER U,; GRUBLER Y,; CHERVIN A, ; GOLDBERG V, ; GOYA R,; HENTGES ST,; LOW MJ, ; HOLSBOER F, ; STALLA GK,; ARZT E,
Revista:
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Editorial:
NATL ACAD SCIENCES
Referencias:
Lugar: Washington DC, USA; Año: 2003 p. 34 - 1039
ISSN:
0027-8424
Resumen:
Pituitary tumor development involves clonal expansion stimulated by
hormones and growth factors/cytokines. Using mRNA differential display,
we found that the bone morphogenetic protein (BMP) inhibitor noggin is
down-regulated in prolactinomas from dopamine D2-receptor-deficient
mice. BMP-4 is overexpressed in prolactinomas taken from dopamine
D2-receptor-deficient female mice, but expression of the highly
homologous BMP-2 does not differ in normal pituitary tissue and
prolactinomas. BMP-4 is overexpressed in other prolactinoma models,
including estradiol-induced rat prolactinomas and human prolactinomas,
compared with normal tissue and other pituitary adenoma types (Western
blot analysis of 48 tumors). BMP-4 stimulates, and noggin blocks, cell
proliferation and the expression of c-Myc in human prolactinomas,
whereas BMP-4 has no action in other human pituitary tumors. GH3 cells
stably transfected with a dominant negative of Smad4 (Smad4dn; a BMP
signal cotransducer) or noggin have reduced tumorigenicity in nude mice.
Tumor growth recovered in vivo when the Smad4dn expression was lost, proving that BMP-4/Smad4 are involved in tumor development in vivo.
BMP-4 and estrogens act through overlapping intracellular signaling
mechanisms on GH3 cell proliferation and c-myc expression: they had
additive effects at low concentrations but not at saturating doses, and
their action was inhibited by blocking either pathway with the
reciprocal antagonist (i.e., BMP-4 with ICI 182780 or 17β-estradiol with
Smad4dn). Furthermore, coimmunoprecipitation studies demonstrate that
under BMP-4 stimulation Smad4 and Smad1 physically interact with the
estrogen receptor. This previously undescribed prolactinoma pathogenesis
mechanism may participate in tumorigenicity in other cells where
estrogens and the type β transforming growth factor family have
important roles.

